Tag Archives: BIO

PRNews

People’s Republic of China Approves Proliant Biologicals for the Importation of New Zealand BSA

ANKENY, Iowa and FEILDING, New Zealand, July 17, 2017 /PRNewswire/ — Following a recent Chinese decision, centered around New Zealand Origin Bovine Material, Proliant Biologicals is now eligible to ship its New Zealand Bovine Serum Albumin (BSA) into the country.  The change comes after months of restricting the importation of any bovine blood products of New Zealand origin into the country.

With the Chinese border now open to Proliant New Zealand and its BSA, it is Proliant’s goal to help support the continued growth of the Chinese Diagnostic, Life Science, Vaccine, and Cell Culture markets, among others.  As the population continues to increase and as more and more Chinese gain access to healthcare, the development of these markets is as vital as ever. 

Proliant Biologicals, and its New Zealand BSA manufacturing facility, is in a unique position to help service the expanding Chinese Life Science industries.  The facility, located in Feilding, is registered with the MPI and is Traceability Certified by the International Serum Industry Association (ISIA).  With dual manufacturing facilities (New Zealand and US), Proliant is the only BSA manufacturer in the world who holds ISIA traceability certificates.

For more information pertaining to Proliant’s New Zealand BSA and its facility, please utilize the following link: http://www.proliantbiologicals.com

Grade

Material Origin

Part Number

Standard Grade pH 7.0

New Zealand

69100

Reagent Grade (Fatty Acid-Free)

New Zealand

Coming Soon

About Proliant Biologicals, Inc.

Proliant is the world’s premier manufacturer of animal extracts and consistent, reliable, traceable Bovine Serum Albumin (Fraction V).  All Proliant bovine albumins are made from Proliant-collected USDA/MPI Edible grade Plasma; and are protease-free, IgG-free, low endotoxin & bioburden with outstanding solubility/filterability characteristics.

Proliant Biologicals is part of the LGI group of companies, premier manufacturer of protein ingredients for food, health, nutrition and biologicals.  Proliant along with American Protein Corporation, BHJ Corporation and Boyer Valley Corporation are privately held companies of the Lauridsen Group Incorporated.

Source: Proliant Biologicals, Inc.

PRNews

Mr. Colin Hopper Receives IPA Lifetime Achievement Award in PDT Clinical Research

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Mr. Colin Hopper was the recipient of the 2017 LIFETIME ACHIEVEMENT AWARD IN PDT CLINICAL RESEARCH.

Mr. Colin Hopper is currently the Senior Lecturer/Consultant Oral and Maxillofacial Surgeon and unit head off oral and maxillofacial surgery at University College London (UCL), Eastman Dental Institute London.  He is a Consultant Head and Neck Surgeon, University College London Hospitals and until recently Senior Research Fellow at the National Medical Laser Centre London.

Mr. Hopper spent his early career pioneering clinical protocols to confirm safety and efficacy of PDT for oncological and antimicrobial applications. Since 1991, Mr. Hopper has been working in the National Medical Centre leading a variety of research projects on the use of photodynamic therapy in the treatment of oral squamous cell carcinoma. This clinical PDT program is currently one of the world’s largest and longest running programs, documenting over 400 treatments involving the three main photosensitizers.

Mr. Hopper, long recognized for his expertise in clinical PDT, is the principal investigator on a series of ethically approved projects, including in a number of developing countries. His work has resulted in numerous publications helping to establish a clear role for PDT treatment in a variety of neoplastic conditions in the head and neck. This work has advanced rapidly by the development of interstitial treatment of tumours using image guidance systems developed with the department of imaging and medical physics.  Other related areas of research include fluorescence diagnostics (optical techniques for tissue interrogation), the use of PDT in the treatment of non-malignant conditions such as lymphangioma and the use of PDT for antimicrobial applications. Mr. Hopper dedicates considerable personal time to lecturing, mentoring and training next generations of PDT clinicians globally.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

please contact: ipasecretary@internationalphotodynamic.com

PRNews

Dr. Pilar Acedo Nunez is Recipient of 2017 IPA Early Investigator Award

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Dr. Pilar Acedo Nunez was the recipient of the 2017 IPA EARLY INVESTIGATOR AWARD.

Dr. Pilar Acedo Nunez was recognized for her exceptional research at the University College London (England) involving combination photosensitizers and photodynamic therapy which demonstrated improved efficacy and response rates in vitro and in vivo. She has been awarded several research grants, prizes and awards including a competitive two-year postdoctoral fellowship (2015) sponsored by Ramon Areces Foundation (Spain) and the Peter Samuel Royal Free Trust Fund (UK) to study at UCL under Professor Sandy MacRobert and Professor Steve Pereira.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Dr. Natalia Inada is Recipient of 2017 Award for PDT Clinical Trial Excellence

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Dr. Natalia Inada was the recipient of the 2017 AWARD FOR PDT CLINICAL TRIAL EXCELLENCE.

Dr. Natalia Inada was recognized for her leadership and fundamental role over a number of innovative Photodynamic Therapy (PDT) based trials at the Institute of Physics of Sao Carlos (Brazil). These multi-centre clinical trials involve hundreds of Latin American patients and relate to the non-surgical PDT-based treatment of skin cancer and the non-surgical PDT-based treatment of cervical intraepithelial neoplasia (CIN), for the prevention of cervical cancer. These Photodynamic treatment protocols are intended to offer minimally invasive, superior outcomes for patients in underdeveloped countries with limited public health systems. Dr. Inada was also the recent recipient of the Mercosul Science and Technology Award for the “CerCa 150 System®: a non-surgical option for cervical intraepithelial neoplasia and condyloma treatment”.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies. The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Merck Awards EUR1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation (GFI)

DARMSTADT, Germany, July 5, 2017 /PRNewswire/ —

  • Two projects are awarded funds to advance the fertility field 
  • Professor Lunenfeld honored with Merck Lifetime Achievement Award 
  • The company is committed to driving innovation through evolving the product portfolio and investing in potential breakthrough research 

Merck, a leading science and technology company, today announced its commitment to award EUR1.25 million to research projects in the field of fertility, supporting the advancement of medical science through the Grant for Fertility Innovation (GFI) in 2017. Launched as the first of the Merck Grants for Innovation in 2009, Merck’s GFI is providing encouragement for innovation and support for scientists to realize projects that could potentially lead to the next breakthrough in the fertility treatment area. This year, the GFI Award Ceremony included the announcement of the Merck Lifetime Achievement Award in Fertility Innovation.

To recognize Merck’s belief in progress through innovation, the GFI awardees were revealed in a ceremony at the European Society of Human Reproduction and Embryology (ESHRE), currently taking place in Geneva, Switzerland. The winning projects truly reflect the global nature of the program, ranging from research in Italy to Brazil.

Professor Bruno Lunenfeld, a speaker at the GFI 2017 ceremony, was honored with the Merck Lifetime Achievement Award for his revolutionary work within the fertility field since 1954. At the ceremony he provided an overview on the discovery of human gonadotropins from postmenopausal urine.

“Professor Lunenfeld’s pioneering achievements in the field of fertility are a huge inspiration to us at Merck. It is highly motivating to consider the breadth of his contributions. For more than 60 years now, his expertise and experience have greatly contributed to our efforts to improve the quality of patient care,” said Belen Garijo, member of the Executive Board of Merck and CEO Healthcare, when presenting Professor Lunenfeld with the Merck Lifetime Achievement Award.

The research investments through the GFI is core to the innovation strategy of the biopharma business of Merck, and in the quest for increased success rates within fertility treatment. In this year’s GFI, two winning projects were selected from 46 global proposals with the common goal of advancing the fertility field. The GFI was launched in 2009, and is dedicated to transforming innovative translational fertility research projects into actual solutions with the aim to improve fertility treatment outcomes. Merck proudly announced the 2017 GFI awardees during the ceremony:

  • Endometrial Notch pathway as a novel target for improving implantation efficiency; Luisa Campagnolo, PhD
  • Pharmacogenetic algorithm for individualized controlled ovarian stimulation (iCOS) in assisted reproductive technology cycles; Caio Parente Barbosa, MD, PhD, MS and Matheus Roque, MD

About the Grant for Fertility Innovation (GFI) 

Merck announced the initiation of the GFI program in 2009 to support the advancement of science and innovative technologies in the fertility field. This grant is awarded every year to translational research projects that can potentially improve baby birth rate for the benefit of the patients. Each project is blinded and evaluated by a jury of experts according to five criteria: support to increase baby birth rate; innovative research; scientific rationale; feasibility and practical utility.

For further information about the GFI and how to apply for next year’s grants, please visit: http://www.grantforfertilityinnovation.com

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck 

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR15.0 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Contact:
Dr. Raphaela Farrenkopf
+49-6151-72-2274

(Logo: http://photos.prnewswire.com/prnh/20160913/406891LOGO )